MEDomics: Sales for Mitochondrial Disease Molecular Testing Increases 20-fold in Three Months

December 19, 2010

MEDomics is seeing acceptance of its clinical tests for mitochondrial disease among the mitochondrial disease community.

Azusa, CA (PRWEB) December 17, 2010

MEDomics provides NextGen sequence-based DNA diagnostic testing to enable personalized medicine in the genomics era and is transforming diagnostic testing for mitochondrial diseases. Entering its third year of operations, MEDomics is seeing acceptance of its clinical tests for mitochondrial disease among the mitochondrial disease community. The firm experienced a 20-fold increase in clinical sample value submitted during the three month period of September through November.

“October was the first month that clinical revenue has exceeded collaborative R&D and grant revenue, stated Craig Camp, MEDomics Chief Operating and Financial Officer”. “Sales actually quadruplicated in November as a result of continued physician support of our technology and our clinical tests.

According to Steve Sommer, MD, PhD, Founder and President, “Our molecular diagnostic tests are based on the revolutionary Next Generation sequencing technology, which greatly improves the utilization of blood tests to evaluate patients suspected to have mitochondrial diseases. The use of more sensitive tests can lead to better diagnosis, and eliminate painful and expensive muscle biopsies. The Next Generation mitochondrial genome test for mtDNA mutations can offer physicians efficient diagnosis of mitochondrial diseases, enable rational therapy, and provide prognostic information for enhanced risk counseling.”

MEDomics, LLC (http://www.medomics.com) is a molecular diagnostic laboratory founded in 2008 by Steve S. Sommer, MD, PhD, with the mission of providing Mutation Expert-based Diagnosis (“MED”) to support the physician in delivering personalized medicine based on analysis of the patient’s genome (“omics”). MEDomics was the first CLIA Certified Laboratory specializing in the clinical diagnostic application of Next Generation sequencing. The mutation experts at MEDomics provide quality interpretation to aid the practicing physician. The staff at MEDomics “live and breathe” mitochondrial medicine.

Contact Information:

MEDomics, LLC

426 N. San Gabriel Ave.

Azusa, CA 91702


Phone: (626) 804-3645

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2010/12/prweb4903084.htm

Source: prweb

comments powered by Disqus